Reprotech and TMRW Life Sciences enter into Business Combination to Create the Most Comprehensive Technology-Enabled Cryostorage Company in Fertility

The strategic business combination couples Reprotech's 35+ years of cryostorage leadership with TMRW's next-generation technology to deliver a fully integrated digital solution for frozen eggs, embryos, and sperm at scale

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Reprotech and TMRW Life Sciences today announced a strategic business combination, bringing together two leaders in fertility storage and technology to create the industry's most comprehensive, technology-enabled company for the management and cryostorage of frozen eggs, embryos, and sperm. The combined business will operate under the Reprotech banner, which will now feature the TMRW, Matcher, and Cryologix brands.

Louis Villalba, current Chief Executive Officer of TMRW Life Sciences, will serve as Chief Executive Officer of the combined organization. Brad Senstra, current Chief Executive Officer of Reprotech, will serve as Chief Operating Officer.

Reprotech brings more than 35 years of leadership in long-term cryostorage, a national network of offsite biorepositories, and established digital witnessing and billing platforms, including Matcher and Cryologix. TMRW contributes its Digital Specimen Management platform, advanced automated and manual storage solutions, and commercial partnerships with leading fertility networks — creating a complete digital solution for the tracking, management, and storage of frozen eggs, embryos, and sperm.

Together, the combined organization will safeguard more than one million fertility specimens, partner with approximately 75% of fertility centers nationwide, support more than 50% of U.S. patient cycles, and operate eight offsite storage facilities.

As the fertility industry continues shifting from fresh to frozen cycles, clinics are managing cryostorage volumes far beyond what much of their original infrastructure was designed to support. This trend is increasing demand for storage solutions that can scale safely, accurately, and efficiently. With complementary strengths across technology, operations, and clinical partnerships, the combined organization is well positioned to support the evolving needs of fertility clinics and patients across the United States, with the opportunity to expand internationally over time.

"There is clear industrial logic in bringing Reprotech and TMRW together," said Luis A. Fernandez, Chairman of the Board of Reprotech. "We are building a company designed to meet the evolving demands of the fertility industry by combining state of the art infrastructure, trusted service, and next-generation technology. Following our investment in IMT Matcher and now with TMRW's Digital Specimen Management platform, we are creating a fully technology-enabled cryostorage offering that can meet clinics where they are today while helping define where the industry is going tomorrow."

The combined organization supports a broad range of fertility clinics, health systems, and patient populations nationwide. Reprotech partners with leading university and hospital-based fertility centers, fertility preservation centers, and many independent fertility practices, while TMRW works with some of the largest fertility networks in the country. The business combination strengthens the combined company's national reach and expands its ability to provide clinics and patients with a unified, flexible solution across both onsite and offsite storage environments.

"At TMRW, our mission has always been to safeguard life's most precious cells and advance the standard of care," said Louis Villalba, incoming Chief Executive Officer of the combined organization. "By joining forces with Reprotech, we have the opportunity to bring together trusted infrastructure, national scale, and digital innovation in a way that is truly differentiated in the fertility market. I'm excited to lead this next chapter and help build the future of fertility cryostorage."

Throughout the integration process, clinic partners and patients can expect continuity of care, clear communication, expanded digital capabilities, and continued investment in safety, service, and innovation. With a shared commitment to patient safety, regulatory excellence, and continuous innovation, the combined organization is poised to set a new standard for fertility cryostorage.

"With the combined resources of Reprotech and TMRW, we are now able to accelerate the technology and products we offer our partners," said Brad Senstra, Chief Operating Officer of the combined company. "We are moving forward with a truly talented team that will make specimen management safer, streamlined, and more cost-effective for fertility clinics and their patients."

About Reprotech
Reprotech is the leading provider of products and services for the safe-guarding, management and long-term storage of reproductive specimens. Reprotech's integrated portfolio includes five purpose-built biorepositories across the U.S., advanced cryostorage management technologies and global digital chain-of-custody solutions. Reprotech partners with fertility centers to reduce specimen storage burden and liability, streamline billing and consent management, strengthen traceability, and manage risk. Built on decades of experience and driven by continuous innovation, Reprotech's rigorous compliance standards and operational excellence set the benchmark for protecting specimens from clinic to cryostorage, ensuring customers have secure options for preserving what matters most, today and for the future.

About TMRW Life Sciences
Founded in 2018, TMRW Life Sciences, Inc. is a fertility technology company digitizing the IVF lab with the world's first automated platform for the safe management and storage of frozen sperm, eggs, and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care by reducing potential points of failure associated with manual systems. Named Fast Company's #1 Most Innovative Biotech Company in 2022, TMRW has been adopted by leading fertility clinics across the United States and United Kingdom.

Media Contact: Joy Zardecki, [email protected]

SOURCE Reprotech, LLC